Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC-1898 in Advanced Solid Tumors
NCT07252661Phase 1Not yet recruiting
- Sponsor
- AccSalus Biosciences, Inc.
- Start
- Jan 2027
- Primary completion
- Jun 2028
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of ACC-1898 in solid tumor, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and 6 more (2 arms), sponsored by AccSalus Biosciences, Inc. Primary endpoints: Incidence of Dose-Limiting Toxicities and Treatment-Emergent Adverse Events. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
ACC-1898
03
Conditions
solid tumorhepatocellular carcinoma (HCC)renal cell carcinoma (RCC)medullary thyroid carcinoma (MTC)differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT07252661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07252661.